Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers lifted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 2.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 53,113 shares of the company’s stock after acquiring an additional 1,236 shares during the quarter. Rhumbline Advisers’ holdings in Mirum Pharmaceuticals were worth $2,196,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of MIRM. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock worth $67,000 after acquiring an additional 318 shares in the last quarter. Legato Capital Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 7.9% during the 4th quarter. Legato Capital Management LLC now owns 13,395 shares of the company’s stock valued at $554,000 after buying an additional 977 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock worth $421,000 after purchasing an additional 1,003 shares in the last quarter. R Squared Ltd bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $69,000. Finally, Secure Asset Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 9.3% in the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock valued at $1,651,000 after purchasing an additional 3,406 shares during the last quarter.

Insiders Place Their Bets

In other news, COO Peter Radovich sold 2,627 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the sale, the chief operating officer now owns 26,961 shares of the company’s stock, valued at approximately $1,300,059.42. This represents a 8.88 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Christopher Peetz sold 9,102 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $438,898.44. Following the transaction, the chief executive officer now owns 115,920 shares of the company’s stock, valued at $5,589,662.40. The trade was a 7.28 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,915 shares of company stock worth $1,897,920. Corporate insiders own 22.87% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on MIRM shares. Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Finally, HC Wainwright lifted their price target on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a “buy” rating in a research report on Friday. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $58.20.

Mirum Pharmaceuticals Stock Down 3.3 %

NASDAQ MIRM opened at $45.99 on Tuesday. The stock has a fifty day moving average of $47.05 and a 200-day moving average of $43.43. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The stock has a market capitalization of $2.25 billion, a P/E ratio of -22.77 and a beta of 0.96. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $54.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The company had revenue of $99.41 million during the quarter, compared to analyst estimates of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.